The state has enjoyed success funding and building life sciences companies, and the new Indiana Biosciences Research Institute should give it a further boost, according to panelists Friday at IBJ's Life Sciences Power Breakfast.
Lilly expects to soon announce late-stage clinical trial results for two biotech drugs designed to slow the inflammation caused by autoimmune diseases. By the end of the year, it will announce results for a third.
Michael A. Byers' Tooth Bank is one of a tiny group of U.S. companies catering to the latest iteration of stem cell therapy: harvesting stem cells from the pulp inside baby teeth and extracted wisdom teeth, then culturing, freezing and storing them at a cryostorage facility for later use.
Indiana's life sciences companies are spending four times more on medical research than the state's hospitals, doctors and univerities are receiving from such companies for research projects. That means Indiana is missing out on more than $80 million a year.
Last week’s Supreme Court ruling upholding the tax credits for Obamacare is just the latest in a string of developments that have kept employers from ditching their group health plans, as many predicted they would.
For at least 20 years, Republicans have been pushing for giving tax credits to help individuals buy health insurance. The Supreme Court's latest Obamacare ruling does Republicans the favor of preserving them.
London Mayor Boris Johnson is proposing a $16 billion fund to encourage growth of emerging health-care companies in the United Kingdom in an effort to catch up to biotechnology clusters in the United States.
The Indiana-based company has taken the name Zimmer Biomet Holdings Inc. and will trade under the ticker symbol to "ZBH" on Monday. Zimmer Holdings Inc. agreed to buy privately-held Biomet in April 2014.
Cigna said Anthem's a risky bet due to fallout from its massive data breach, lawsuits that accuse it of conspiring to inflate prices, and lack of a growth strategy. But Wall Street thinks this deal is going to happen, unless Cigna can find another buyer.
The Obama administration could write a new regulation. Congress could pass a short law. States could run a low-cost exchange. But the politics might require all parties to let the tax credits die while they try to pin the blame on the other side.